All News

Article

ACR21 – Day 3 Report

Jack Cush, MD

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

David Liew Tweet
drdavidliew
Oh, also VTEs. Not designed to do this, but: - We don't use 10mg bid & we shouldn't start - 5mg bid looks just fine - In fact, in patients with a VTE history, 5mg bid is numerically similar (?better) to TNFi Somehow, VTE in tofa is an overshadowed non-event! #ACR21 @RheumNow https://t.co/fvMSg49kk6
Aurelie Najm Tweet
AurelieRheumo
Different drugs may target different pathways in PsA! S-cell proteomic biomarkers in SELECT-1 PsA study: 💥UPA targets ▶️ Adaptive immunity, bone metabolism pathways 💥ADA targets ▶️ innate immunity pathways. Paving the ground for personalised therapy? #ACR21 #Abst1816 @RheumNow https://t.co/hyMP4PtUnM
sheila Tweet
RHEUMarampa
An artificial neural network for detection of radiographic #sacroiliitis in axSpA? @DrPoddubnyy 📌Specificity - 93.9% 📌Sensitivity - 78.7% Potential tool for interpreting SIJ in nonspecialized ctrs or clinical trials This is a game changer!🤓 @RheumNow #ACR21 #ACRBest abs1919 https://t.co/2li0dNWtLc
Aurelie Najm Tweet
AurelieRheumo
And it’s a wrap!! Time for a pool game🎱 Delighted to have been reporting for @RheumNow alongside an amazing faculty! and delighted to have been able to be around amazing colleagues to attend #ACR21 convergence! See you all next year, hopefully for real! 🤞🏼 https://t.co/JBoKd7zNvl
Akhil Sood MD Tweet
AkhilSoodMD
Abstr 1677 Miwa & colleagues studied the effect of bDMARDs on cholesterol levels in RA patients - bDMARDs may affect HDL levels - no significant effect was seen on LDL #ACR21 @RheumNow https://t.co/yb35HMDlxN
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its faculty.
Richard Conway Tweet
RichardPAConway
Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but may be residual confounding due to burden disease/comorbidities. Abstr#1942 #ACR21 @RheumNow https://t.co/UzOwuKKFmX
Richard Conway Tweet
RichardPAConway
Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disease control. Consistent across all rheumatic and non-rheumatic diseases. Abstr#1946 #ACR21 @RheumNow https://t.co/D1Ppb58fB8
Janet Pope Tweet
Janetbirdope
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Eric Dein Tweet
ericdeinmd
Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX? https://t.co/I5WmCECq7v
Richard Conway Tweet
RichardPAConway
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
Richard Conway Tweet
RichardPAConway
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×